** Clarity Pharmaceuticals CU6.AX rises 1.4% to A$3.315; set for third straight session of gains
** Stock has gained 13.5% since Wednesday after Jefferies upgraded to "buy" from "hold"
** Brokerage said Phase 2 trial data shows clinical-stage radiopharmaceutical's 64Cu-Sartate in patients with neuroendocrine tumours identified more lesions than competition
** YTD, CU6 down 20.5%
(Reporting by Shruti Agarwal in Bengaluru)
((Shruti.Agarwal@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.